戈沙妥珠单抗 米托坦 帕金森病 酪氨酸激酶抑制剂 端粒酶抑制剂 塞普替尼 莫洛利单抗 依沃西单抗 帕博利珠单抗
#今日行业热点#①The Lancet：Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
(资料图)
临床试验：戈沙妥珠单抗（sacituzumab govitecan）用于激素受体阳性和人表皮生长因子受体2（HER2）阴性转移性乳腺癌(TROPiCS-02)的总生存率:一项随机、开放标签、多中心、Ⅲ期试验
②The Lancet Diabetes and Endocrinology：Human POT1 protects the telomeric ds-ss DNA junction by capping the 5′ end of the chromosome
临床试验：米托坦（Mitotane）辅助治疗与监测低级别局限性肾上腺皮质癌(ADIUVO):一项国际、多中心、开放标签、随机、Ⅲ期试验和观察性研究
③The Lancet Neurology：Identification of genetic risk loci and causal insights associated with Parkinson"s disease in African and African admixed populations: a genome-wide association study
全基因组关联研究：非洲和非洲混合人群中与帕金森病相关的遗传风险位点和因果关系的识别
④The Lancet Haematology：Measuring chronic myeloid leukaemia TKI-related toxic effects in the real world: a systematic review and critical assessment of content validity of patient-reported outcome measures
通过对患者报告内容有效性的系统回顾和评估测量慢性粒细胞白血病TKI（酪氨酸激酶抑制剂）相关的毒性作用
⑤The Lancet Infectious Diseases：Seasonal vaccination with RTS,S/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial
临床试验：在布基纳法索和马里对5岁以下儿童接种带有或不带有季节性疟疾化学预防的RTS,S/AS01E疫苗:一项双盲、随机、对照、Ⅲ期试验
⑥The Lancet Respiratory Medicine：Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials
临床分析：识别脓毒症的分子表型:两项前瞻性观察队列分析和两项随机对照试验的二次分析
⑦全球首款端粒酶抑制剂GRN163L（Imetelstat）的新药申请获FDA受理，用于低危骨髓增生异常综合征（LR-MDS）患者的输血依赖性贫血
⑧RET抑制剂塞普替尼（selpercatinib）用于初治、RET突变型晚期或转移性甲状腺髓样癌（MTC）的III期LIBRETTO-531研究达到主要终点
⑨靶向于CD47的单克隆抗体和LSC抑制剂莫洛利单抗Magrolimab用于急性髓系白血病（AML）的美国临床研究已被FDA叫停
⑩PD-1/VEGF双特异性抗体依沃西单抗国际多中心注册性III期研究即将在中国启动，评估依沃西单抗联合化疗对比帕博利珠单抗联合化疗用于转移性鳞状非小细胞肺癌（sq-NSCLC）的安全性和有效性
科学探索的世界充满挑战，AtaGenix致敬每一位拓荒者，更致力于成为您信赖的合作伙伴！
标签：
